Research programme: deubiquitinating enzyme inhibitors - Hybrigenics/Servier
Latest Information Update: 21 Jan 2014
At a glance
- Originator Hybrigenics; Servier
- Mechanism of Action Ubiquitin-protein ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 20 Jan 2014 Early research is ongoing in France
- 12 Oct 2011 Early research in Undefined indication in France (unspecified route)